Burkholderia multivorans Exhibits Antibiotic Collateral Sensitivity

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Jerilyn Nicole FlanaganTodd R Steck

Abstract

Burkholderia multivorans is a member of the Burkholderia cepacia complex whose members are inherently resistant to many antibiotics and can cause chronic lung infections in patients with cystic fibrosis. A possible treatment for chronic infections arises from the existence of collateral sensitivity (CS)-acquired resistance to a treatment antibiotic results in a decreased resistance to a nontreatment antibiotic. Determining CS patterns for bacteria involved in chronic infections may lead to sustainable treatment regimens that reduce development of multidrug-resistant bacterial strains. CS has been found to occur in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Here, we report that B. multivorans exhibits antibiotic CS, as well as cross-resistance (CR), describe CS and CR networks for six antibiotics (ceftazidime, chloramphenicol, levofloxacin, meropenem, minocycline, and trimethoprim-sulfamethoxazole), and identify candidate genes involved in CS. Characterization of CS and CR patterns allows antibiotics to be separated into two clusters based on the treatment drug to which the evolved strain developed primary resistance, suggesting an antibiotic therapy strategy of switching between members of these two cl...Continue Reading

References

Feb 6, 2008·Antimicrobial Agents and Chemotherapy·Todd A DaviesRobert K Flamm
Dec 23, 2008·Biochimica Et Biophysica Acta·Anne H Delcour
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Apr 9, 2010·Clinical Microbiology Reviews·John J Lipuma
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg
Aug 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Amanda F GoddardPradeep K Singh
Sep 15, 2012·Infection and Drug Resistance·Derek S SarovichTalima Pearson
Mar 13, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Joshua R StokellTodd R Steck
Sep 27, 2013·Science Translational Medicine·Lejla Imamovic, Morten O A Sommer
Oct 31, 2013·Molecular Systems Biology·Viktória LázárCsaba Pál
Apr 4, 2014·Bioinformatics·Anthony M BolgerBjoern Usadel
Sep 24, 2014·Proceedings of the National Academy of Sciences of the United States of America·Seungsoo KimRoy Kishony
Nov 14, 2014·Science Translational Medicine·Christian MunckMorten O A Sommer
Mar 31, 2015·Trends in Microbiology·Csaba PálViktória Lázár
Apr 9, 2015·PLoS Biology·Ayari Fuentes-HernandezRobert Beardmore
Sep 15, 2015·Nature Chemical Biology·Patrick R GonzalesGautam Dantas
Dec 8, 2015·Evolutionary Applications·Roderich RoemhildHinrich Schulenburg
Sep 14, 2016·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Katherine A Rhodes, Herbert P Schweizer
May 26, 2017·Molecular Biology and Evolution·Camilo BarbosaGunther Jansen
Feb 15, 2018·Antimicrobial Agents and Chemotherapy·Kiara HeldColin Manoil
Mar 3, 2018·Antonie van Leeuwenhoek·J Nicole Flanagan, Todd R Steck
Apr 25, 2018·Nature Ecology & Evolution·Danna R GiffordR Craig MacLean
Sep 24, 2018·Trends in Microbiology·Kimberly M Davis, Ralph R Isberg
Jan 20, 2019·Nature Communications·Daniel NicholJacob G Scott

❮ Previous
Next ❯

Citations

Sep 5, 2020·Pharmacoepidemiology and Drug Safety·Elisa Martín-MerinoDolores Montero-Corominas
Jun 8, 2021·Antimicrobial Agents and Chemotherapy·L G KavanaughT R Steck

❮ Previous
Next ❯

Datasets Mentioned

BETA
PRJNA264318

Software Mentioned

SAMtools
IndelAligner
Trimmomatic
Bowtie2
Python
ETEST
Picard
VCFtools
MEM
GraphPad Prism

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.